- Home
- ACST
ACST
Acasti Pharma Inc.
as 07-26-2024 4:00pm EST
Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.
| Founded: | N/A | Country: | Canada |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 30.6M | IPO Year: | N/A |
| Target Price: | $6.00 | AVG Volume (30 days): | 13.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.72 - $3.59 | Next Earning Date: | 08-09-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Acasti Pharma Inc. News
ACST Breaking Stock News: Dive into ACST Ticker-Specific Updates for Smart Investing
Zacks
16 days ago
Is Acasti Pharma (ACST) Outperforming Other Medical Stocks This Year?
Simply Wall St.
25 days ago
Is Acasti Pharma (NASDAQ:ACST) In A Good Position To Invest In Growth?
GlobeNewswire
a month ago
Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial
GlobeNewswire
a month ago
Acasti Announces Year-End 2024 Financial Results, Provides Business Update
GlobeNewswire
2 months ago
Acasti Pharma to Attend BIO International Convention 2024
Simply Wall St.
2 months ago
Insider Stock Buying Reaches US$2.50m On Acasti Pharma
Insider Monkey
4 months ago
12 Best Biotech Penny Stocks to Invest In
GlobeNewswire
5 months ago
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
Compare ACST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACST Acasti Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.